Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease
- PMID: 25393520
- DOI: 10.1164/rccm.201408-1545OC
Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease
Abstract
Rationale: Although intermittent, three-times-weekly therapy is recommended for the initial treatment of noncavitary nodular bronchiectatic Mycobacterium avium complex (MAC) lung disease, supporting data are limited.
Objectives: To evaluate the clinical efficacy of intermittent therapy compared with daily therapy for nodular bronchiectatic MAC lung disease.
Methods: A retrospective cohort study of 217 patients with treatment-naive noncavitary nodular bronchiectatic MAC lung disease. All patients received either daily (n = 99) or intermittent therapy (n = 118) that included clarithromycin or azithromycin, rifampin, and ethambutol.
Measurements and main results: Modification of the initial antibiotic therapy occurred more frequently in the daily therapy group than in the intermittent therapy group (46 vs. 21%; P < 0.001); in particular, ethambutol was more frequently discontinued in the daily therapy group than in the intermittent therapy group (24 vs. 1%; P ≤ 0.001). However, the rates of symptomatic improvement, radiographic improvement, and sputum culture conversion were not different between the two groups (daily therapy vs. intermittent therapy: 75 vs. 82%, P = 0.181; 68 vs. 73%, P = 0.402; 76 vs. 67%, P = 0.154, respectively). In addition, the adjusted proportion of sputum culture conversion was similar between the daily therapy (71.3%; 95% confidence interval, 59.1-81.1%) and the intermittent therapy groups (73.6%; 95% confidence interval, 62.9-82.2%; P = 0.785).
Conclusions: These results suggest that intermittent three-times-weekly therapy with a macrolide, rifampin, and ethambutol is a reasonable initial treatment regimen for patients with noncavitary nodular bronchiectatic MAC lung disease. Clinical trial registered with www.clinicaltrials.gov (NCT 00970801).
Trial registration: ClinicalTrials.gov NCT00970801.
Keywords: Mycobacterium avium complex; ethambutol; macrolides; nontuberculous mycobacteria; treatment.
Comment in
-
Therapy for Mycobacterium avium complex lung disease. It ain't perfect, but it's progress.Am J Respir Crit Care Med. 2015 Jan 1;191(1):14-6. doi: 10.1164/rccm.201411-2078ED. Am J Respir Crit Care Med. 2015. PMID: 25551346 No abstract available.
Similar articles
-
Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study.Ann Am Thorac Soc. 2014 Jan;11(1):23-9. doi: 10.1513/AnnalsATS.201308-266OC. Ann Am Thorac Soc. 2014. PMID: 24298907 Clinical Trial.
-
Multicentre, open label, randomised controlled trial comparing intermittent versus daily treatment for non-cavitary nodular/bronchiectatic Mycobacterium avium complex lung disease with rifampicin, ethambutol and clarithromycin (iREC): study protocol.BMJ Open Respir Res. 2019 May 30;6(1):e000434. doi: 10.1136/bmjresp-2019-000434. eCollection 2019. BMJ Open Respir Res. 2019. PMID: 31258920 Free PMC article.
-
Response to Switch from Intermittent Therapy to Daily Therapy for Refractory Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease.Antimicrob Agents Chemother. 2015 Aug;59(8):4994-6. doi: 10.1128/AAC.00648-15. Epub 2015 May 18. Antimicrob Agents Chemother. 2015. PMID: 25987622 Free PMC article.
-
Diagnosis and treatment of infections due to Mycobacterium avium complex.Semin Respir Crit Care Med. 2008 Oct;29(5):569-76. doi: 10.1055/s-0028-1085708. Epub 2008 Sep 22. Semin Respir Crit Care Med. 2008. PMID: 18810690 Review.
-
Risk-benefit assessment of therapies for Mycobacterium avium complex infections.Drug Saf. 1999 Aug;21(2):137-52. doi: 10.2165/00002018-199921020-00006. Drug Saf. 1999. PMID: 10456381 Review.
Cited by
-
Drug-drug interactions in the management of non-tuberculous mycobacterial infections.Front Microbiol. 2024 Sep 5;15:1468383. doi: 10.3389/fmicb.2024.1468383. eCollection 2024. Front Microbiol. 2024. PMID: 39301186 Free PMC article. Review.
-
Management challenges and outcomes for non-tuberculous mycobacterial pulmonary disease.IJTLD Open. 2024 Jul 1;1(7):332-334. doi: 10.5588/ijtldopen.24.0140. eCollection 2024 Jul. IJTLD Open. 2024. PMID: 39035424 Free PMC article. No abstract available.
-
Bigger problems from smaller colonies: emergence of antibiotic-tolerant small colony variants of Mycobacterium avium complex in MAC-pulmonary disease patients.Ann Clin Microbiol Antimicrob. 2024 Mar 18;23(1):25. doi: 10.1186/s12941-024-00683-6. Ann Clin Microbiol Antimicrob. 2024. PMID: 38500139 Free PMC article.
-
Variables associated with antibiotic treatment tolerance in patients with Mycobacterium avium complex pulmonary disease.Respir Res. 2024 Mar 11;25(1):123. doi: 10.1186/s12931-024-02752-y. Respir Res. 2024. PMID: 38468274 Free PMC article. Review.
-
Detecting circulating microbial cell-free DNA by next-generation sequencing in patients with Mycobacterium avium complex-lung disease: A pilot study.Tzu Chi Med J. 2023 Nov 7;36(1):67-75. doi: 10.4103/tcmj.tcmj_191_23. eCollection 2024 Jan-Mar. Tzu Chi Med J. 2023. PMID: 38406566 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
